Bryce Alan H, Agarwal Neeraj, Beltran Himisha, Hussain Maha H, Sartor Oliver, Shore Neal, Antonarakis Emmanuel S, Armstrong Andrew J, Calais Jeremie, Carducci Michael A, Dorff Tanya Barauskas, Efstathiou Jason A, Gleave Martin, Gomella Leonard G, Higano Celestia, Hope Thomas A, Iagaru Andrei, Morgans Alicia K, Morris David S, Morris Michael J, Petrylak Daniel P, Reiter Robert E, Rettig Matthew B, Ryan Charles J, Sellinger Scott B, Spratt Daniel E, Srinivas Sandy, Tagawa Scott T, Taplin Mary-Ellen, Yu Evan Y, Zhang Tian, McKay Rana R, Koo Phillip J, Crawford E David
Department of Medical Oncology and Therapeutics Research, City of Hope Phoenix, Phoenix, Arizona, USA.
Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA.
Cancer. 2025 Jan 1;131(1):e35612. doi: 10.1002/cncr.35612. Epub 2024 Dec 1.
Current US clinical practice guidelines for advanced prostate cancer management contain recommendations based on high-level evidence from randomized controlled trials; however, these guidelines do not address the nuanced clinical questions that are unanswered by prospective trials but nonetheless encountered in day-to-day practice. To address these practical questions, the 2024 US Prostate Cancer Conference (USPCC 2024) was created to generate US-focused expert clinical decision-making guidance for circumstances in which level 1 evidence is lacking. At the second annual USPCC meeting (USPCC 2024), a multidisciplinary panel of experts convened to discuss ongoing clinical challenges related to 5 topic areas: biochemical recurrence; metastatic, castration-sensitive prostate cancer; poly [ADP-ribose] polymerase inhibitors; prostate-specific membrane antigen radioligand therapy; and metastatic, castration-resistant prostate cancer. Through a modified Delphi process, 34 consensus recommendations were developed and are intended to provide clinicians who manage prostate cancer with guidance related to the implementation of novel treatments and technologies. In this report, the authors review the areas of consensus identified by the USPCC 2024 experts and evaluate ongoing unmet needs regarding translational application of the current clinical evidence.
美国当前关于晚期前列腺癌管理的临床实践指南包含了基于随机对照试验的高级别证据所提出的建议；然而，这些指南并未涉及前瞻性试验未解决但在日常实践中却会遇到的细微临床问题。为了解决这些实际问题，2024年美国前列腺癌会议（USPCC 2024）应运而生，旨在针对缺乏一级证据的情况制定以美国为重点的专家临床决策指南。在第二届年度USPCC会议（USPCC 2024）上，一个多学科专家小组齐聚一堂，讨论与5个主题领域相关的当前临床挑战：生化复发；转移性、去势敏感性前列腺癌；聚[ADP-核糖]聚合酶抑制剂；前列腺特异性膜抗原放射性配体疗法；以及转移性、去势抵抗性前列腺癌。通过改良的德尔菲法，制定了34条共识建议，旨在为管理前列腺癌的临床医生提供有关新治疗方法和技术实施的指导。在本报告中，作者回顾了USPCC 2024专家确定的共识领域，并评估了当前临床证据在转化应用方面仍未满足的需求。
